STRUCTURAL BIOLOGY SHARED RESOURCE The Structural Biology Shared Resource (STRBIO) provides a comprehensive platform of expertise, education, and infrastructure that enables LCCC researchers to perform cutting-edge structural biological studies. LCCC members have all the resources needed to determine macromolecular structures using X-ray crystallography, biomolecular NMR, and single-particle cryo-electron microscopy (cryoEM). This mission is accomplished through seven complementary components: 1) macromolecular X-ray crystallography, 2) multi-dimensional nuclear magnetic resonance (NMR) spectroscopy, 3) cryo-electron microscopy, 4) structural bioinformatics, 5) protein expression and purification, 6) synthesis of peptides and peptidomimetics, and 7) biophysical measurements of macromolecular properties in solution and their interactions. Each component of STRBIO is managed by an on-site director with a Ph.D. and years of relevant scientific and managerial experience. All core directors hold ranks of Assistant Research Professor or higher and most teach graduate-level classes in their respective disciplines. John Sondek (MT) continues as faculty director of STRBIO and leads this team of experienced directors. Dr. Sondek has over 20 years of experience in structural biology and drug discovery and meets bimonthly with core directors as a group to coordinate efforts and develop strategic plans. The STRBIO was used by 131 users last year. LCCC members accounted for 34% of the use. There are no alternatives to STRBIO on campus or at nearby academic institutions. In fact, STRBIO attracts numerous users from outside the UNC system due to its competitive rates and extensive services. STRBIO requests $119,631 for this SR, approximately 6% of the total operating budget of $1.9M. To accomplish its mission STRBIO will continue to expand services into areas of high demand, areas that take advantage of the inherent synergies embodied among the STRBIO components, and areas predicted to provide major advances in cancer biology including new fragment-based drug discovery and expanding capacity to label proteins isotopically.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Ma, Shaohua; Paiboonrungruan, Chorlada; Yan, Tiansheng et al. (2018) Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci 1434:164-172
Aung, Kyaw L; Fischer, Sandra E; Denroche, Robert E et al. (2018) Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res 24:1344-1354
Suh, Junghyun L; Watts, Brian; Stuckey, Jacob I et al. (2018) Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. Biochemistry 57:2140-2149
Brock, William J; Beaudoin, James J; Slizgi, Jason R et al. (2018) Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. Int J Toxicol 37:144-154
Thomas, Nancy E; Edmiston, Sharon N; Tsai, Yihsuan S et al. (2018) Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. Am J Dermatopathol :
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Hall, Marissa G; Marteau, Theresa M; Sunstein, Cass R et al. (2018) Public support for pictorial warnings on cigarette packs: an experimental study of US smokers. J Behav Med 41:398-405
Thorsson, V├ęsteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Wu, Bing; Zhang, Song; Guo, Zengli et al. (2018) RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. Immunity 49:886-898.e5
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10

Showing the most recent 10 out of 1525 publications